CF Drug Developer Insmed to Participate in Rare Disease Roundtable

Patrícia Silva, PhD avatar

by Patrícia Silva, PhD |

Share this article:

Share article via email
rare disease roundtable

rare disease roundtableLeerink Partners, a specialty investment bank in the field of healthcare, recently extended an invitation to Insmed Incorporated, the biopharmaceutical company behind a highly promising liposomal amikacin formulation to treat Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF), to participate in a Rare Disease Roundtable. The event will take place on October 1, 2014 at the Le Parker Meridian Hotel in New York City.

Insmed has confirmed their attendance for a fireside chat between the company’s President and CEO, Will Lewis, and Leerink’s analyst, Joseph P. Schwartz. Their discussion will be broadcasted live via webcast on at 2:20 p.m. EST. A replay will be available on the website up to 90 days after the live broadcast.

While Cystic Fibrosis is a high-profile disease in the news, it is in fact a rare disease. Approximately 30,000 people in the United States suffer from CF — a relatively small number compared to other diseases, such as cancer, heart disease, and diabetes. Because of its small patient population, funding and support for research and development into new CF therapies have proven to be a challenge in the past. Events such as Leerink Partners’ Rare Disease Roundtable help to embolden efforts in the CF drug development and advocacy communities to continue their critical work toward advancing new therapies that will eventually cure the disease.

[adrotate group=”1″]

Respiratory infections oftentimes prove to be difficult to treat and manage among CF patients because of  uncontrolled mucus production and buildup in lung airways. In related news, ARIKACE is Insmed’s flagship inhalation product, indicated for nontuberculous mycobacteria respiratory infections, and Pseudomonas aeruginosa infections in CF patients. This product has shown great promise during clinical trials. Patients who participated in two of Insmed’s trials continue to observe improvements in their Pseudomonas infections by taking inhaled Arikace once a day.